Xeris Pharmaceuticals | XERS - Cash And Equivalent


Xeris Pharmaceuticals reported $111.04M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Celltrion KRW 29.65B 799.42B Jun/2025
Cspc Pharmaceutical CNY 7.57B 793.73M Jun/2025
Deva Holding AS TRY 775.92M 574.67M Sep/2023
Dianthus Therapeutics USD 51.09M 4.9M Dec/2025
Divis Laboratories Ltd INR 4.15B 31.87B Mar/2025
Eli Lilly USD 7.27B 2.52B Dec/2025
Kangmei Pharma CNY 1.18B 278M Sep/2025
Knight Therapeutics CAD 76.45M 5.43M Dec/2025
Laboratorios Farma EUR 46.11M 18.92M Jun/2025
Malin Corporation EUR 62.1M 26.4M Dec/2024
Medical Developments International AUD 17.84M 219K Jun/2025
Nektar Therapeutics USD 15.12M 25.92M Dec/2025
Neuren Pharmaceuticals AUD 5.91M 2.76M Jun/2025
Organigram Holdings CAD 7.58M 20.62M Dec/2025
Pacira USD 158.54M 10.96M Dec/2025
Perrigo USD 432.1M 22.1M Sep/2025
Pharma Mar EUR 17.82M 3.78M Dec/2025
Qiagen NV USD 1.36B 621.78M Sep/2025
Sartorius EUR 389.9M 429.1M Sep/2025
Sino Biopharmaceutical CNY 3.38B 2.09B Dec/2024
Supernus Pharmaceuticals USD 151.37M 6.66M Sep/2025
Tilray USD 264.83M 43.16M Jun/2025
Zealand Pharma A/S 4.58B 1.4B Dec/2025
Zz Pientze Pharmaceu CNY 1.77B 376.03M Jun/2025